Drug intelligence / Profile preview

SP0306 ADC

Development stage: Unknown
Lead developer: Protheragen
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SP0306 ADC is a dual-targeting antibody-drug conjugate (ADC) developed by Protheragen for the treatment of inflammatory bowel disease (IBD). The therapeutic candidate is designed to simultaneously target interleukin-23 (IL-23) and tumor necrosis factor-like ligand 1A (TL1A), both of which are validated drivers of inflammation in Crohn's disease and ulcerative colitis. By combining the specificity of monoclonal antibodies with a potent payload, SP0306 ADC aims to provide a more targeted and effective intervention for patients with refractory IBD. The program is currently in Phase I clinical development.

Targets

TL1A (TNF-like cytokine 1A)IL-23 (Interleukin-23)

Beyond the preview

Go deeper on SP0306 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP0306 ADC.

Explore the full profile